Compare United States Copper Index Fund (CPER) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs TG Therapeutics Inc — how do they compare? United States Copper Index Fund trades at $40.31 (market cap $708.28M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 11.5× United States Copper Index Fund's market cap, and United States Copper Index Fund is more actively traded (339,046 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 49 Days and TG Therapeutics Inc for 16 Days on average.
| CPER | TGTX | |
|---|---|---|
Market Cap | $708.28M | $8.16B |
Volume | 339,046 | 1,735,121 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $59.06 |
52-Week Low | $30.27 | $26.94 |
Typical Hold Time | 49 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER is trading at $39.46, down 0.88% on the day with a bearish technical signal from moving averages. The stock shows neutral oscillator readings with RSI levels around 33-36 indicating neither overbought nor oversold conditions. Recent news highlights strong copper demand driven by AI infrastructure needs, though copper miners have faced recent price pressure. Key support and resistance levels cluster tightly around $39-40, suggesting potential for near-term breakout or breakdown.
The copper sector faces mixed signals with strong long-term demand fundamentals from AI and electrification trends, but near-term volatility from supply dynamics and market sentiment. Investment opportunity exists in copper's critical role in technology infrastructure, while risks include commodity price fluctuations and mining operational challenges that could impact stock performance.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
